JPRN-UMIN000000493未知2 期
A Phase II study of docetaxel (T) and cyclophosphamide(C) as adjuvant chemotherapy for patients with high risk, node negative, early stage breast cancer - JECBC04
Japan East Cancer Center Breast Cancer Consortium0 个研究点目标入组 50 人开始时间: 2006年10月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 70years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •Male A history of other malignancies within the last 5 years except for adequately treated non-melanoma skin cancer or carcinoma in situ of the cervix Bilateral breast cancer Inflammatory breast cancer A history of hypersensitivity reaction to drugs formulated with Polysorbate 80 Uncontrolled medical conditions (e.g., malignant hypertension, congestive heart failure, renal failure, myocardial infarction in the previous 6 months, treatment required arrhythmia, infection, hemorrhage) Grade 2-4 peripheral neuropathy Pleural or pericardial effusion requiring treatment Severe peripheral edema. Significant interstitial pneumonia or pulmonary fibrosis by CT scan or X-ray Patients who require concurrent treatment by corticosteroids except for premedication. Evere psychiatric disorders Pregnant or lactating women Patients judged by the investigator to be unfit to be enrolled into the study Prior chemotherapy or radiation therapy for other cancer within 3 years including neo-adjuvant chemotherapy for locally advanced breast cancer.
研究者
相似试验
已完成
2 期
Phase II study of the combination of docetaxel, cisplatin plus S-1(DCS) for advanced or recurrent gastric cancer(KDOG 0601)Gastric cancerJPRN-UMIN000001119Department of Gastroenterology, Kitasato University School of Medicine45
已完成
不适用
Phase I/II study of the combination of docetaxel, CDDP and S-1 in patients with unresectable advanced gastric cancerunresectable advanced gastric cancerJPRN-C000000080Fourth Department of Internal Medicine, Sapporo Medical University40
未知
2 期
A phase II study of combination Docetaxel, Cisplatin, and S-1 as neoadjuvant chemotherapy for advanced gastric cancer.advanced gastric cancerJPRN-UMIN000000801Dept. of Internal Medicine(4)30
已完成
2 期
A phase II study of neoadjuvant docetaxel/cyclophosphamide (DC) followed by epirubicin/cyclophosphamide (EC) for triple-negative breast cancerbreast cancerJPRN-UMIN000011031Tokyo Women's Medical University34
已完成
2 期
Multicenter phase II study of docetaxel/cisplatin/bevacizumab combination therapy in patients with advanced non-squamous non-small cell lung cancer (TORG1016)JPRN-UMIN000004368Thoracic Oncology Research Group47